ACURA PHARMACEUTICALS, INC
ACUR evidence brief
What we can confirm
- Market Cap:
- $26K
What it means
What to watch
Prepared research question
What matters most for ACUR—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
Market Cap
$26K
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Run ACURA PHARMACEUTICALS, INC through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available ACURA PHARMACEUTICALS, INC facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Financials
Short Interest
as of May 1, 2026- % of float
- 1.2%
- Days to cover
- 0.7
- Shares short
- 89,846
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
ACUR short interestFrequently asked questions
Who is the CEO of ACURA PHARMACEUTICALS, INC?
Mr. Robert B. Jones is the chief executive officer of ACURA PHARMACEUTICALS, INC (ACUR).
Where is ACURA PHARMACEUTICALS, INC headquartered?
ACURA PHARMACEUTICALS, INC (ACUR) is headquartered in Palatine, IL, United States.
What therapeutic areas does ACURA PHARMACEUTICALS, INC focus on?
ACURA PHARMACEUTICALS, INC develops therapies across Immunology, Pain, Musculoskeletal.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.